London and New York, NY., 21 December, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar dry eye disease market.
Announced today that the Company is participating in the Biotech Showcase in San Francisco, California from January 9-11, 2023 and will be hosting institutional investor and partnering meetings both at the event and online.
Dr. Gary Jacob, Chief Executive Officer, Dr. Raj Patil, Chief Scientific Officer and the OKYO team, will give a corporate presentation and host 1×1 institutional investor and partnering meetings during the event.
Presentation Date/Time: Monday January 9, 2023, at 4:30 pm PT
1×1 meetings: January 9-11
Online 1×1 meetings: January 18-19
Location: Hilton San Francisco Union Square in San Francisco, Yosemite-A
To schedule a meeting with management, investors can register on the Biotech Showcase website .
OKYO Pharma Limited
Gary S. Jacob, Chief Executive Officer
+44 (0)20 7495 2379
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned